SYSTEMATIC REVIEW article
Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series
- 1Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 2Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 3Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, United States
Introduction: The 2019 novel coronavirus (COVID-19) has been declared a public health emergency worldwide. The objective of this systematic review was to characterize the clinical, diagnostic, and treatment characteristics of hospitalized patients presenting with COVID-19.
Methods: We conducted a structured search using PubMed/Medline, Embase, and Web of Science to collect both case reports and case series on COVID-19 published up to April 24, 2020. There were no restrictions regarding publication language.
Results: Eighty articles were included analyzing a total of 417 patients with a mean age of 48 years. The most common presenting symptom in patients who tested positive for COVID-19 was fever, reported in up to 62% of patients from 82% of the analyzed studies. Other symptoms including rhinorrhea, dizziness, and chills were less frequently reported. Additionally, in studies that reported C-reactive protein (CRP) measurements, a large majority of patients displayed an elevated CRP (60%). Progression to acute respiratory distress syndrome (ARDS) was the most common complication of patients testing positive for COVID-19 (21%). CT images displayed ground-glass opacification (GGO) patterns (80%) as well as bilateral lung involvement (69%). The most commonly used antiviral treatment modalities included, lopinavir (HIV protease inhibitor), arbidiol hydrochloride (influenza fusion inhibitor), and oseltamivir (neuraminidase inhibitor).
Conclusions: Development of ARDS may play a role in estimating disease progression and mortality risk. Early detection of elevations in serum CRP, combined with a clinical COVID-19 symptom presentation may be used as a surrogate marker for the presence and severity of the disease. There is a paucity of data surrounding the efficacy of treatments. There is currently not a well-established gold standard therapy for the treatment of diagnosed COVID-19. Further prospective investigations are necessary.
Late in December 2019 and early in January 2020, reports of a very progressive pneumonia-like respiratory syndrome, starting in Wuhan, China, induced global health concerns (1). Soon after the onset of disease, it was found that the pathogen was a new member of the coronaviridae family, named SARS-COV-2 which is now called 2019-n-CoV (2). The respiratory syndrome caused by 2019-n-CoV is called COVID-19. COVID-19 is characterized by low-grade fever, cough, dyspnea, lymphopenia, and ground-glass opacities on chest CT scan (3, 4). COVID-19 is a highly contagious disease, probably an aerosol born one, with human to human transmission capacity which has implicated many countries all around the world (5). In this review article, we systematically surveyed case reports and case series from many countries in the world to give a picture of the epidemiology, clinical presentations, laboratory changes, imaging findings, diagnostic criteria, treatments, outcomes, prognostic factors, and risk factors of COVID-19 in hospitalized patients.
This review conforms to the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) statement (6).
We carried out systematic searches of the literature in the following bibliographical databases: PubMed/Medline, Embase, and Web of Science. Search criteria included case reports and case series articles published up to April 24, 2020, and there were no restrictions regarding publication language. We used Google Translate for eligible articles published in languages other than English. The search terms for our review were: COVID-19, severe acute respiratory syndrome coronavirus 2, novel coronavirus, SARS-CoV-2, nCoV disease, SARS2, COVID-19, 2019-nCoV, coronavirus disease-19, coronavirus disease 2019, and 2019 novel coronavirus.
Studies included in the review met the following criteria: prospective or retrospective descriptive case reports and case series of COVID-19 in the hospital setting which included diagnostic methods, clinical manifestations, laboratory features, treatment, and outcomes. Articles describing experimental approaches as well as reviews and publications without peer-review processes were excluded.
All potentially relevant articles were screened in two stages for eligibility. In the first stage, the titles and abstracts of potentially relevant articles were screened independently by two reviewers (YF, PJ). In the second stage of assessment, the full text of those abstracts which met the inclusion criteria was retrieved and independently reviewed by the same authors. Disagreements and technical uncertainties were discussed and resolved between review authors (AT, SH, MA, MJN).
The extracted data included bibliographic data, patient demographics (e.g., age and gender), radiological and laboratory findings, treatment protocols, and medical consequences. Two authors (AT, SH) independently extracted the data from the selected studies. The data was jointly reconciled, and disagreements were discussed and resolved between review authors (YF, PJ, MA, MJN).
The critical appraisal checklist for case reports provided by the Joanna Briggs Institute (JBI) was used to perform a quality assessment of the studies (7).
As illustrated in Figure 1, our systematic search resulted in an initial number of 6,004 of potentially relevant articles, of which 1,033 were excluded by title and abstract evaluation. Applying the inclusion/exclusion criteria to the full-text documents, 80 articles were eligible for inclusion in the systematic review. 42 case reports and 38 case series from 19 countries were identified with a total of 417 unique cases of COVID-19 with a mean age of 48 years (Table 1). The included case reports were published because of the following reasons: they reported (1) new CT findings; (2) new clinical manifestations; (3) new laboratory findings, (4) new treatment outcomes; (5) atypical manifestations and some were the first one in a specific country. Based on the JBI tool, the included studies had a low risk of bias. RT-PCR COVID-19 was present in 79 (95%) articles as inclusion criteria. In addition to RT-PCR, a CT scan served as a diagnostic tool in 16 (19%) of papers. Reported comorbidities included hypertension, diabetes, cardiovascular disease, and pulmonary disease. Hypertension was investigated the most, studied in 22/83 (26.5%) of papers. Of the 16 COVID-19 positive patients found in the studies investigating hypertension, 44 patients were hypertensive (19%) (Table 2). Lymphopenia was reported in 24 studies which identified 83/185 (45%) of COVID-19 positive patients. Additionally, in studies that reported C-reactive protein (CRP) measurements, a large majority of patients displayed an elevated CRP (60%). CT images commonly displayed ground-glass opacification (GGO) patterns (82%) as well as bilateral lung involvement (66%). Progression to acute respiratory distress syndrome (ARDS) was the most common complication of patients testing positive for COVID-19. We found 11/83 (13.2%) reports on Acute Respiratory Distress Syndrome (ARDS), 18 of 86 (21%) investigated cases had ARDS. Mortality outcomes were difficult to assess; only 10 studies showed mortality data in which 17/108 (16%) COVID-19 patients died. A wide range of therapeutic modalities was tried across studies, with antiviral treatments being the most used.
Common antiviral treatment modalities included lopinavir (HIV protease inhibitor), arbidiol hydrochloride (influenza fusion inhibitor), and oseltamivir (neuraminidase inhibitor). In Table 3 we summarize all of the drugs used.
The 2019 novel coronavirus has been declared a public health emergency worldwide. The World Health Organization (WHO) declared COVID-19 a pandemic affecting 110 countries around the world with a continued global spread. The 2019-nCoV is likely to be transmitted by asymptomatic individuals (86). Asymptomatic transfer leads to lower prevalence estimates and higher transmission rates in the community. Until universal screening and vaccination become available, it is necessary to trace close contacts of those testing positive for COVID-19 and quarantining contacts to prevent asymptomatic transmission.
According to the articles we included, 2019-nCoV can only be transferred from person to person (87). Chen et al. suggested that they had no evidence of vertical transmission from mother to child (36). Any person infected with 2019-nCoV can develop a clinical course of Covid-19. However, it is reported to cause the most severe symptoms such as respiratory failure in older men with comorbidities (88). Children, teenagers, and younger people mostly showed a mild presentation of the disease (89).
Based on our reviewed articles, hypertension, diabetes, cardiovascular disease, and pulmonary disease were the most common morbidities among COVID-19 patients. This point was also mentioned in Alraddadi et al. study about MERS-CoV patients (90). They showed that individuals with comorbidities like diabetes, smoking, and cardiovascular disease were associated with a more severe clinical course (90). According to Yang et al., chronic diseases can debilitate the immune system and make pro-inflammatory conditions, leading to more severe infection and subsequently higher mortality rates (91).
According to the included studies, the most common clinical manifestations were fever, cough, dyspnea, and myalgia or fatigue. Less common clinical manifestations included nausea or vomiting, dizziness, rhinorrhea, and chills. Liu et al. reported that infants had mild clinical manifestations and a better prognosis. Furthermore, some asymptomatic cases were seen among children.
The most common abnormal laboratory changes were lymphopenia, high concentrations of C-reactive protein, and elevated levels of aspartate aminotransferase; however, we do not know the exact pathogenesis and the reason for these alterations. Laboratory abnormalities may indicate the severity of disease and developing complications. According to Huang et al., most patients with secondary infection had a procalcitonin level >0.5 ng/Ml and ICU patients had higher levels of prothrombin time and D-dimer (92). Also, Liu et al. mentioned using hypoalbuminemia, lymphopenia, high concentrations of CRP, and elevated LDH to predict the severity of acute lung injury (3). Higher levels of angiotensin II are also proposed to be related to acute lung injury (3). Meanwhile, non-survivors are suggested to have higher D-dimer and FDP levels, longer PT and aPTT, and lower fibrinogen and antithrombin levels (93).
CT scan as a diagnostic tool can be used to evaluate the severity of pulmonary involvement and monitor clinical progression. CT scan has good sensitivity and can be used to establish COVID-19 diagnosis in patients who are highly suspicious based on epidemiologic history and clinical manifestations but have negative PCR-based test results (12, 94). It is important to highlight that the CT scan can be normal during initial days, and a normal CT scan in a suspected case would never definitely rule out the diagnosis of COVID-19 (95). Moreover, the CT scan is dynamic in patients with COVID-19 and changes rapidly (13, 17, 19). The earliest abnormal finding in the CT scan is the appearance of ground-glass opacities in peripheral and sub-pleural areas (96). As the disease progresses, the GGO's will expand and distribute more, most commonly to the right lower lung lobes. Later findings include consolidations, paving patterns, thickening of lobar fissures, and adjacent pleura. Pleural effusion, hilar lymphadenopathies, and mediastinal lymphadenopathies are not common findings and have only been reported scarcely (40). Lung pathology can progress to a “white lung” with low functional capacity or heal with some fibrotic remnants (40). Dynamic changes in the lungs seen on CT imaging will continue even after the patient's discharge (96). CT scan findings have prognostic value in some patients, as Shi et al. have reported, deterioration on follow-up CT scan, old age, male sex, and underlying comorbidities are associated with poor prognosis.
ARDS was the most common complication among the confirmed COVID-19 patients; the development of ARDS increased the risk of patient mortality (97). Huang et al. reported that the median time from onset of symptoms to the development of ARDS was 9 days (92). Other complications were acute cardiac injury, acute kidney injury, secondary infection, and shock that leads to multiple organ failure (98, 99). ICU patients in comparison to non-ICU patients were also more likely to have complications (100). The mortality rate was higher in critically ill patients as well as in older patients with comorbidities and ARDS. Yang et al. reported that the median duration from ICU admission to death was 7 days (97). The window between the presentation to the time of ICU admission and/or development of ARDS is an optimal time for medical intervention.
Also, the results of the current study are in comparison with the recent large patient cohort studies in the aspect of comorbidities, clinical manifestations, laboratory, and radiological findings, however, there are some differences (101, 102). In a study by Richardson et al., a more detailed analysis of the patient's vital signs, ICU interventions, outcome characteristics, and risk factors were reported (101). According to their study, among the patients who were discharged or had died during hospitalization, 14.2% were treated in the ICU, 12.2% received invasive mechanical ventilation, 3.2% were treated with kidney replacement therapy, and 21% died. Moreover, Grasselli et al. indicated that Older patients (age ≥ 64 years) had higher mortality than younger patients (age ≤ 63 years) (36%vs 15%) (102).
There are many challenges in COVID-19 therapeutic strategies. There is currently no cure for COVID-19. However, pharmacologic and non-pharmacologic symptom management and supportive care measures should be given to all patients with symptomatic COVID-19. Other various therapeutic strategies have been trialed in patients with COVID-19 to slow disease progression. There is a paucity of data surrounding the efficacy of treatments. Of the case controls and case series we included, antiviral agents including HIV protease inhibitors (lopinavir and ritonavir) as well as anti-influenza compounds (oseltamivir and arbidol) were used as treatment regimens. Unfortunately, we didn't have enough information about the efficacy of each regimen; however, according to some studies, anti-HIV based medications could have benefits in more rapid improvement of clinical manifestations and decrease in viral load (13, 16, 19).
A limitation of this review relates to the potential risk of bias. Bias occurs in the case reports/series studies because their results are not representative and do not represent the truth. A further limitation is that the conclusions are limited due to the case reports and case series. We did not include observational studies and randomized controlled trial (RCT)/quasi-randomized studies, because another study being conducted by the authors. Furthermore, the focus of the reviewed case reports and case series was mainly on the clinical description of the patients with COVID-19, but detailed information on the treatment outcomes and medical consequences were rarely provided. Also, the case number included in this systematic review is low compared with the currently published patient cohort, and this may lead to the declining clinical significance of this manuscript. Finally, our results are limited to younger adults who had been hospitalized during the 4–5 first months of the COVID-19 pandemic.
In conclusion, we discussed the clinical symptoms, laboratory abnormalities, common comorbidities, imaging modalities, and potential therapeutic options in COVID-19. We indicated that the most common symptoms were fever, cough, and dyspnea, but some young infected cases had no signs or symptoms. ARDS was the most common reported complication and was associated with poor prognosis. In the wake of the COVID-19 pandemic, countries are scrambling to produce enough RT-PCR diagnostic tests. Diagnostic information from other surrogate markers would be valuable if markers proved to be sensitive and specific. Namely, we learned that laboratory data like CRP may not only be related to the severity of the disease, but it may be predictive of disease outcomes. Further studies are needed to relate quantified elevations in CRP to disease severity. Due to the high sensitivity of the CT scan, it is considered as a good diagnostic tool. However, it should be kept in mind that a normal CT scan will never rule out the diagnosis of COVID-19 in a highly suspicious case based on history and clinical findings. Lastly, there are different therapeutic strategies for COVID-19 patients, but we don't have enough data for their efficacy. Additional investigations including randomized controlled trials will be necessary to further our understanding of the treatment of COVID-19.
Data Availability Statement
All datasets presented in this study are included in the article/ supplementary material.
MN and MM designed the study and revised the manuscript. MN, AT, MA, YF, PJ, SH, and TC performed the search, data extraction, statistical analysis, and wrote the first draft of the manuscript.
This study was financially supported by Research Department of the School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Grant number: 22960).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. (2020) 395:565–74. doi: 10.1016/S0140-6736(20)30251-8
3. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. (2020) 63:364–74. doi: 10.1007/s11427-020-1643-8
6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. (2009) 151:264–9. doi: 10.7326/0003-4819-151-4-200908180-00135
9. Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis. (2020) jiaa077. doi: 10.1093/infdis/jiaa077. [Epub ahead of print].
13. Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. (2020). 92:461–3. doi: 10.1002/jmv.25711
16. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of Coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Kor Med Sci. (2020) 35:e79. doi: 10.3346/jkms.2020.35.e89
17. Shi H, Han X, Zheng C. Evolution of CT manifestations in a patient recovered from 2019 novel coronavirus (2019-nCoV) pneumonia in Wuhan, China. Radiology. (2020) 295:20. doi: 10.1148/radiol.2020200269
21. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Medicine. (2020) 8:420–2. doi: 10.1016/S2213-2600(20)30076-X
22. Winichakoon P, Chaiwarith R, Liwsrisakun C, Salee P, Goonna A, Limsukon A, et al. Negative nasopharyngeal and oropharyngeal swab does not rule out COVID-19. J Clin Microbiol. (2020) 58:e00297-20. doi: 10.1128/JCM.00297-20
23. Zhang Z, Li X, Zhang W, Shi ZL, Zheng Z, Wang T. Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases. Virol Sin. (2020). doi: 10.1007/s12250-020-00203-8. [Epub ahead of print].
27. Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. (2020) 382:872–4. doi: 10.1056/NEJMc2001272
32. Bai SL, Wang JY, Zhou YQ, Yu DS, Gao XM, Li LL, et al. Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province. Zhonghua Fang Xue Za Zhi. (2020) 54:E005. doi: 10.3760/cma.j.issn.0253-9624.2020.0005
33. Cai JH, Wang XS, Ge YL, Xia AM, Chang HL, Tian H, et al. First case of 2019 novel coronavirus infection in children in Shanghai. Zhonghua Za Zhi. (2020) 58:E002. doi: 10.3760/cma.j.issn.0578-1310.2020.0002
34. Zeng LK, Tao XW, Yuan WH, Wang J, Liu X, Liu ZS. First case of neonate infected with novel coronavirus pneumonia in China. Zhonghua Za Zhi. (2020) 58:E009. doi: 10.3760/cma.j.issn.0578-1310.2020.0009
35. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. (2020) 395:514–23. doi: 10.1016/S0140-6736(20)30154-9
36. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. (2020) 395:809–15. doi: 10.1016/S0140-6736(20)30360-3
39. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. BioScience Trends. (2020) 14:64–8. doi: 10.5582/bst.2020.01030
40. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. (2020) 200343. doi: 10.1148/radiol.2020200343. [Epub ahead of print].
41. Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest radiographic and CT findings of the 2019 Novel Coronavirus Disease (COVID-19): analysis of nine patients treated in Korea. Kor J Radiol. (2020) 21:494–500. doi: 10.3348/kjr.2020.0132
42. Stoecklin BS, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Eurosurveillance. (2020) 25:2000094. doi: 10.2807/1560-7917.ES.2020.25.6.2000094
43. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. (2020) 382:970–1. doi: 10.1056/NEJMc2001468
45. Tong ZD, Tang A, Li KF, Li P, Wang HL, Yi JP, et al. Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis. (2020) 26:1052–4. doi: 10.3201/eid2605.200198
46. Feng K, Yun YX, Wang XF, Yang GD, Zheng YJ, Lin CM, et al. Analysis of CT features of 15 children with 2019 novel coronavirus infection. Zhonghua Za Zhi. (2020) 58:E007. doi: 10.3760/cma.j.issn.0578-1310.2020.0007
47. Zhang MQ, Wang XH, Chen YL, Zhao KL, Cai YQ, An CL, et al. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Zhonghua Jie He He Hu Xi Za Zhi. (2020) 43:E013. doi: 10.3760/cma.j.issn.1001-0939.2020.0013
48. Liu M, He P, Liu HG, Wang WJ, Li FJ, Chen S, et al. Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. (2020) 43:E016. doi: 10.3760/cma.j.issn.1001-0939.2020.0016
49. Albarello F, Pianura E, Di Stefano F, Cristofaro M, Petrone A, Marchioni L, et al. 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: an uncommon radiological presentation. Int J Infect Dis. (2020) 93:192–7. doi: 10.1016/j.ijid.2020.02.043
50. Asadollahi-Amin A, Hasibi M, Ghadimi F, Rezaei H, SeyedAlinaghi S. Lung involvement found on chest ct scan in a pre-symptomatic person with SARS-CoV-2 infection: a case report. Trop Med Infect Dis. (2020) 5:56. doi: 10.3390/tropicalmed5020056
51. Bhat R, Hamid A, Kunin JR, Saboo SS, Batra K, Baruah D, et al. Chest imaging in patients hospitalized with COVID-19 infection-a case series. Curr Problems Diagn Radiol. (2020). doi: 10.1067/j.cpradiol.2020.04.001. [Epub ahead of print].
53. Wang L, Duan Y, Zhang W, Liang J, Xu J, Zhang Y, et al. Epidemiologic and Clinical characteristics of 26 cases of COVID-19 arising from patient-to-patient transmission in Liaocheng, China. Clin Epidemiol. (2020) 12:387. doi: 10.2147/CLEP.S249903
54. Liu C, Wu C, Zheng X, Zeng F, Liu J, Wang P, et al. Clinical features and multidisciplinary treatment outcome of COVID-19 pneumonia: a report of three cases. J Formosan Med Assoc. (2020). doi: 10.1016/j.jfma.2020.04.008. [Epub ahead of print].
55. Lu S, Lin J, Zhang Z, Xiao L, Jiang Z, Chen J, et al. Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. (2020). doi: 10.1002/jmv.25776. [Epub ahead of print].
56. Lin C, Ding Y, Xie B, Sun Z, Li X, Chen Z, et al. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: the value of CT images in the course of the disease. Clin Imaging. (2020) 63:7–9. doi: 10.1016/j.clinimag.2020.02.008
57. Mousavi SH, Shah J, Giang HTN, Al-Ahdal TMA, Zahid SU, Temory F, et al. The first COVID-19 case in Afghanistan acquired from Iran. Lancet Infect Dis. (2020). doi: 10.1016/S1473-3099(20)30231-0. [Epub ahead of print].
59. Gupta N, Agrawal S, Ish P, Mishra S, Gaind R, Usha G, et al. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. Monaldi Arch Chest Dis. (2020) 90:193–6. doi: 10.4081/monaldi.2020.1294
60. Moreira BL, Brotto MPD, Marchiori E. Chest radiography and computed tomography findings from a Brazilian patient with COVID-19 pneumonia. Rev Socied Brasileira Med Trop. (2020) 53:e20200134. doi: 10.1590/0037-8682-0134-2020
61. Gao X, Yuan Z, Yang D, Li H, Zhang Y, Gao P, et al. A family cluster of severe acute respiratory syndrome coronavirus 2 infections. Eur J Clin Microbiol Infect Dis. (2020) 1:1–5. doi: 10.21203/rs.3.rs-16921/v1
62. Marchand-Senécal X, Kozak R, Mubareka S, Salt N, Gubbay JB, Eshaghi A, et al. Diagnosis and management of first case of COVID-19 in Canada: lessons applied from SARS. Clin Infect Dis. (2020). doi: 10.1093/cid/ciaa227. [Epub ahead of print].
63. Makurumidze R. Coronavirus-19 Disease (COVID-19): a case series of early suspects reported and the implications towards the response to the pandemic in Zimbabwe. J Microbiol Immunol Infect. (2020). doi: 10.1016/j.jmii.2020.04.002. [Epub ahead of print].
66. Li YK, Peng S, Li L-Q, Wang Q, Ping W, Zhang N, et al. Clinical and transmission characteristics of Covid-19—a retrospective study of 25 cases from a single thoracic surgery department. Curr Med Sci. (2020) 40:295–300. doi: 10.1007/s11596-020-2176-2
67. Cheng SC, Chang YC, Fan Chiang YL, Chien YC, Cheng M, Yang CH, et al. First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan. J Formosan Med Assoc. (2020) 119:747–51. doi: 10.1016/j.jfma.2020.02.007
68. Edrada EM, Lopez EB, Villarama JB, Salva Villarama EP, Dagoc BF, Smith C, et al. First COVID-19 infections in the Philippines: a case report. Trop Med Health. (2020) 48:1–7. doi: 10.1186/s41182-020-00203-0
71. Zeng JH, Liu YX, Yuan J, Wang FX, Wu WB, Li JX, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. (2020) 1:1–5. doi: 10.1007/s15010-020-01424-5
75. Tan YP, Tan BY, Pan J, Wu J, Zeng SZ, Wei HY. Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China. J Clin Virol. (2020) 127:104353. doi: 10.1016/j.jcv.2020.104353
76. Hase R, Kurita T, Muranaka E, Sasazawa H, Mito H, Yano Y. A case of imported COVID-19 diagnosed by PCR-positive lower respiratory specimen but with PCR-negative throat swabs. Infect Dis. (2020) 52:423–6. doi: 10.1080/23744235.2020.1744711
77. Huang WH, Teng LC, Yeh TK, Chen YJ, Lo WJ, Wu MJ, et al. 2019 novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan, China. J Microbiol Immunol Infect. (2020). doi: 10.1016/j.jmii.2020.02.009. [Epub ahead of print].
78. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. (2020) 63:706–11. doi: 10.2139/ssrn.3543598
79. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the korean cohort study on COVID-19. J Kor Med Sci. (2020) 35:e142. doi: 10.3346/jkms.2020.35.e142
80. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Kor Med Sci. (2020) 35:e61. doi: 10.3346/jkms.2020.35.e61
81. Kong I, Park Y, Woo Y, Lee J, Cha J, Choi J, et al. Early epidemiological and clinical characteristics of 28 cases of coronavirus disease in South Korea. Osong Public Health Res Perspect. (2020) 11:8–14. doi: 10.24171/j.phrp.2020.11.1.03
82. Lee NY, Li CW, Tsai HP, Chen PL, Syue LS, Li MC, et al. A case of COVID-19 and pneumonia returning from Macau in Taiwan: clinical course and anti-SARS-CoV-2 IgG dynamic. J Microbiol Immunol Infect. (2020). doi: 10.1016/j.jmii.2020.03.003. [Epub ahead of print].
83. Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. (2020). doi: 10.1016/S1473-3099(20)30200-0. [Epub ahead of print].
85. Li CX, Wu B, Luo F, Zhang N. Clinical study and CT findings of a familial cluster of pneumonia with Coronavirus Disease 2019 (COVID-19). Sichuan da Xue Xue Bao. (2020) 51:155–8. doi: 10.12182/20200360107
87. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. (2020) 382:1199–207. doi: 10.1056/NEJMoa2001316
88. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7
89. Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, et al. Clinical and computed tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2. J Infect. (2020) 80:394–400. doi: 10.1016/j.jinf.2020.02.017
90. Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, Sadran M, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis. (2016) 22:49. doi: 10.3201/eid2201.151340
91. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. (2020) 94:91–5. doi: 10.1016/j.ijid.2020.03.017
92. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
93. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. (2020) 18:844–7. doi: 10.1111/jth.14768
94. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. (2020). doi: 10.1148/radiol.2020200642. [Epub ahead of print].
95. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology. (2020). doi: 10.1148/radiol.2020200463. [Epub ahead of print].
97. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. (2020). doi: 10.1016/S2213-2600(20)30079-5. [Epub ahead of print].
98. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. (2020) 34:101623. doi: 10.1016/j.tmaid.2020.101623
99. Lai CC, Shih T-P, Ko W-C, Tang HJ, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. (2020) 55:105924. doi: 10.1016/j.ijantimicag.2020.105924
100. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–9. doi: 10.1001/jama.2020.1585
101. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. (2020). doi: 10.1001/jama.2020.6775. [Epub ahead of print].
102. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. (2020) 323:1574–81. doi: 10.1001/jama.2020.5394
Keywords: COVID-19, clinical characteristics, diagnosis, treatment, systematic review
Citation: Tahvildari A, Arbabi M, Farsi Y, Jamshidi P, Hasanzadeh S, Calcagno TM, Nasiri MJ and Mirsaeidi M (2020) Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series. Front. Med. 7:231. doi: 10.3389/fmed.2020.00231
Received: 03 April 2020; Accepted: 04 May 2020;
Published: 15 May 2020.
Edited by:Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France
Reviewed by:Patrick Alexander Wachholz, São Paulo State University, Brazil
Meng Rui Lee, National Taiwan University, Taiwan
Copyright © 2020 Tahvildari, Arbabi, Farsi, Jamshidi, Hasanzadeh, Calcagno, Nasiri and Mirsaeidi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
†These authors have contributed equally to this work and share first authorship